ClinicalTrials.govclosed
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
ClinicalTrials.gov study NCT05092802. IPD Sharing: NO. Countries: 1. Publications: 0.
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4
Topics
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.